💼 Equities & ETFs

• 🏭 R3N (French SME) → small caps reinforcement 🇫🇷 (PEA-PME)
• 🌍 Amundi EURO STOXX 50 II ETF → more exposure to European leaders $MSE (+0,73%)
• 
  💰 Vanguard FTSE All-World High Dividend ETF → total return boost $VHYL (+0,31%)
• 
  💻 iShares NASDAQ 100 ETF → tech remains my core 🔥 $CSNDX (+0,88%)
• 
  🔌 Cisco Systems → double entry on US tech $CSCO (-0,46%)
• 
  🧴 Coca-Cola → solid defensive value for dividends 🥤$KO (-1,23%)
• 
  🧬 Zoetis → addition in the animal health sector 💊 $ZTS (+0,7%)
• 
  🏦 S&P Global → diversification into premium finance 💼 $SPGI (+0,34%)
• 
  ✈️ Booking Holdings → light position in high-end tourism 🌴 $BKNG (-2,75%)

🪙 Crypto & Metals

• ₿ Bitcoin → small, quiet DCA $BTC (+1,76%)
• 
  Ξ Ethereum → always faithful to the blockchain $BTC (+1,76%)
• 
  🪙 iShares Physical Gold ETC → a little gold for balance 💎 $IGLN (+1,05%)

💼 Sale

• ⚙️ Carpenter Tech → taking gains on beautiful perf 📈 $CRS (+22,27%)

New acquisitions: $FTNT (+0,03%)
$TTD (+0,26%)
$CMG (+0,45%)
$AJG (+0,7%)
$BRK.B (-0,38%)
$ZTS (+0,7%)

Please let me know what you think of my compilation.

A portfolio that supports long-term, solid growth and remains balanced. The focus is on global diversification, strong dividend payers, stable industry leaders and a targeted admixture of future-oriented stocks, including in the crypto sector.

✅ = already available

👀 = on the watchlist, interesting in terms of price soon

❌ = not yet interesting in terms of price at present

ETF selection

• FTSE All World ✅ = Global basis, broadly diversified. $VWRL (+0,55%)
• 
  MSCI World Tech ✅ = Focus on innovative technology stocks.
• Defense USD 👀 = Stability through defense and security.
• FTSE High Dividend 👀 = Dividend-oriented addition.

Single stock focus

Energy & commodities:

Shell ✅, Chevron 👀, Exxon 👀, Rio Tinto ❌ $SHEL (+2,04%)
$CVX (+0,47%)
$XOM (+0,95%)
$RIO (-0,58%)

Insurers & reinsurers:

Munich Re ✅, Hannover Re 👀, Swiss Re ❌, Allianz ❌, Swiss Life AG ❌ $ALV (+0,06%)
$SREN (-0,08%)
$SLHN (+1,3%)
$HNR1 (+0%)
$MUV2 (+0,09%)

Finance & payment transactions:

Brown & Brown ✅, Marsh & McLennan 👀, Visa ✅, Mastercard ❌, PayPal 👀 $PYPL (+2,15%)
$BRO (+0,01%)
$MMC (-0,72%)
$V (+0,05%)
$MA (-0,01%)

Technology & data:

Alphabet 👀, NVIDIA ❌ , Palantir ❌,

Amazon 👀, Apple ❌, Microsoft ❌, Baidu 👀

Alibaba ✅ $BABA (+3,86%)
$9888 (+2,77%)
$AAPL (+0,3%)
$GOOGL (+1,25%)
$PLTR (+2,84%)
$NVDA (+1,16%)

Health & consumption:

Novo Nordisk ✅, Zoetis 👀, Coca-Cola ❌, Walmart ❌, United Health 👀 $UNH (-0,46%)
$NOVO B (-0,39%)
$ZTS (+0,7%)
$KO (-1,23%)
$WMT (-0,47%)

Automotive & Mobility:

BMW ❌, Mercedes 👀, Tesla ❌ $TSLA (+1,82%)
$BMW (+0,54%)
$MBG (+0,83%)

Cryptos

• XRP ✅ $XRP (+1,91%)
• 
  RENDER ✅ $RENDER (+2,32%)
• 
  Bitcoin (BTC) ❌ $BTC (+1,76%)
• 
  Solana (SOL) ✅ $SOL (+3,11%)
• 
  Ethereum (ETH) ❌ $ETH (+3,33%)

For the weekend

Strategy remains: Patience, discipline and an eye for opportunities.

📈🌾

Hello everyone,

I am currently considering selling my position in UnitedHealth Group $UNH (-0,46%) at a moderate loss and would like to hear your views on this.

I bought in a few months ago as the company was seen in the past as a defensive healthcare giant with a solid balance sheet, stable cash flow and steady dividend growth. Unfortunately, the share price performance since my investment has been disappointing, partly due to increasing regulatory pressure (Medicare Advantage), rising healthcare costs and the general headwind for the US healthcare segment.

I ask myself: is it worth continuing to be patient here or is it better to realize the losses and reallocate capital to more promising stocks?

I would be interested to hear your thoughts on this - how do you see the medium-term prospects for UNH? In your opinion, are there any triggers to watch out for before making a decision?

I would have considered investing the losses in $TMO (+0,14%) or $ZTS (+0,7%) . In my opinion, both are cheaply valued and would fit in with my dividend growth strategy.

Looking forward to a constructive exchange!

Brief profile $ZTS (+0,7%)

• ISIN: US98978V1035
• Sector: Animal Health / Pharmaceuticals
• Market capitalization: approx. USD 75 billion
• Dividend yield: approx. 1.0
• Dividend growth: Ø 20 % p.a. in the last 5 years
• Main customers: Veterinarians, livestock farmers, animal owners worldwide
• Competitive advantage: global market leader in veterinary pharmaceuticals, high brand loyalty

🌱

Why Zoetis? $ZTS (+0,7%)

Zoetis is the world's largest provider of medicines and vaccines for animals. The company was spun off from Pfizer in 2013 - since then, profits have risen continuously.

🐶

Megatrends behind us:

• Growing pet ownership worldwide (esp. USA, Asia)
• Increasing expenditure per animal (premium food, medicine, care)
• Rising global meat consumption → Animal health is important in agriculture
• Veterinary market is more robust than human medicine - less price pressure, stable demand

📈

Why is now a good time to start?

🔻 1.

Share has fallen significantly from its all-time high

• Since 2021 approx. -30% below all-time high (overvalued at 50+ P/E at the time)
• Valuation significantly more attractive again (forward P/E ratio 27-30, depending on estimate)

🧪 2.

Long-term growth intact

• Sales growth recently slowed (especially in China), but no structural problems
• New product pipeline in the areas of parasite protection, painkillers and vaccines

💵 3.

Dividend with strong growth

• Dividend increased by ~20% p.a. in the last 5 years
• Very low payout ratio (~30%) → plenty of scope for further increases
• Buyback program continues → additionally shareholder-friendly

💊 4.

Strong business model

• Operating margin: ~35 %
• Gross margin: over 70
• High pricing power (branded products such as Apoquel, Simparica, Revolution)

📉 Risks

• Veterinary pharmaceuticals can be politically/ethically regulated in emerging markets
• Recent growth slightly below expectations (temporary?)
• Valuation level is not cheap, but justified for quality

✅ Conclusion:

Zoetis is a quality growth stock with a rising dividend - and attractively valued after the correction.

If you want to invest in a defensive growth stock with a long-term tailwind from the pet boom and animal health, Zoetis is a solid addition to your portfolio - both for dividend growth and for value-oriented investors with patience.

I sold my Amphenol bill today for a total of € 967.60 with a profit of € 233.70. At the same time, I sold half of my Broadcom lever bill to secure the profit-taking, with a partial profit of +476.00€. The Siemens leverage certificate was sold for a profit of €784.

Now I bought the Aixtron bill for around €1000, of which around €30 came from dividends.

Aixtron has new special chips based on gallium nitride chips in the pipeline, which are supposed to be particularly energy efficient and have now broken out of the GD50 and GD200 lines, which in my opinion signals a clear upward trend. Aixtron is still quite dominant and has a moat in its technology.

Let's wait a few days/weeks and then some of the profits from my other bills will be invested in dividend stocks.

I currently consider the following dividend stocks to be undervalued in terms of earnings and dividend yield:

$Tokyo Marine Holdings (JP3910660004)

$WTRG (-1%)

$PEP (-1,25%)

$ZTS (+0,7%)

let's see what happens!